Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Ongoing Research Prompts Key Sequencing Considerations in CRC, Pancreatic Cancer

August 11th 2025

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

HER2-Targeted Therapies and Chemoimmunotherapy Continue to Advance Biliary Tract Cancer Management

August 8th 2025

Tanios S. Bekaii-Saab, MD, highlights how HER2-directed agents, chemoimmunotherapy, and biomarker-driven strategies are expanding options for biliary tract cancers.

Dr García-Carbonero on Considerations for Poorly Differentiated GI Neuroendocrine Carcinoma

August 6th 2025

Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Dr Kudo on Evaluating Nivolumab/Ipilimumab in Unresectable HCC

August 5th 2025

Masatoshi Kudo, MD, PhD, discusses a MAIC evaluating nivolumab/ipilimumab vs durvalumab/tremelimumab and atezolizumab/bevacizumab for unresectable HCC.

Rising Incidences, Misconceptions, and Unmet Needs Warrant Awareness for Appendix Cancer

August 5th 2025

Rosario Ligresti, MD, FASGE, discusses the rising incidence of appendix cancer, lack of optimal treatment modalities, and unmet needs for these patients.

BXCL701 Plus Pembrolizumab is Safe and Generates Early Antitumor Activity in Advanced PDAC

August 4th 2025

Benjamin A. Weinberg, MD, FACP, discusses the potential role of BXCL701 plus pembrolizumab in advanced pancreatic ductal adenocarcinoma.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Revisit Every OncLive On Air Episode From July 2025

July 31st 2025

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Namodenoson Surpasses Halfway Enrollment Benchmark in Advanced Pancreatic Cancer Trial

July 30th 2025

Can-Fite has reached the over 50% enrollment milestone for an ongoing phase 2a trial evaluating namodenoson in pancreatic cancer.

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

July 28th 2025

Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.

FDA Grants Priority Review to Perioperative Durvalumab in Resectable Gastric/GEJ Cancer

July 28th 2025

Durvalumab received FDA priority review and breakthrough therapy designation for resectable gastric and GEJ adenocarcinoma.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors

July 25th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated Advanced Pancreatic Cancer

July 25th 2025

VS-7375 earned FDA fast track designation for KRAS G12D–mutant pancreatic ductal adenocarcinoma.

Cabozantinib Wins EU Approval for Previously Treated Advanced Pancreatic and Extrapancreatic Neuroendocrine Tumors

July 24th 2025

The European Commission has approved cabozantinib for the treatment of patients with pancreatic and extrapancreatic neuroendocrine tumors.

The Current and Evolving Role of KRAS G12C and Pan-KRAS Inhibitors in Metastatic PDAC

July 24th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

Dr Finn on Tiragolumab Plus Atezolizumab and Bevacizumab in HCC

July 17th 2025

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD

July 17th 2025

Dr Vogel highlights the importance of the European Commission’s approval of zanidatamab for previously treated, metastatic HER2+ biliary tract cancer.